Cart 0

QY Research

China Urological Cancer Drugs Market Research Report 2017

$3,200.00

Report Published By: QY Research
Publication Date : Feb-17
No. Of Pages: 122

Notes:
Sales, means the sales volume of Urological Cancer Drugs
Revenue, means the sales value of Urological Cancer Drugs

This report studies Urological Cancer Drugs in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc

Market Segment by Regions (provinces), covering
South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China
Split by product Type, with production, revenue, price, market share and growth rate of each type, can be divided into
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
Split by Application, this report focuses on consumption, market share and growth rate of Urological Cancer Drugs in each application, can be divided into
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer

Table of Contents

China Urological Cancer Drugs Market Research Report 2017
1 Urological Cancer Drugs Market Overview
1.1 Product Overview and Scope of Urological Cancer Drugs
1.2 Urological Cancer Drugs Segment by Type
1.2.1 China Production Market Share of Urological Cancer Drugs Type in 2015
1.2.2 Xofigo (Radium Ra 223 Dichloride)
1.2.3 Jevtana (Cabazitaxel)
1.2.4 Inlyta (Axitinib)
1.2.5 Votrient (Pazopanib Hydrochloride)
1.2.6 Sutent (Sunitinib Malate)
1.2.7 Zytiga (Abiraterone Acetate)
1.2.8 Xtandi (Enzalutamide)
1.2.9 Opdivo (Nivolumab)
1.2.10 Provenge (Sipuleucel-T)
1.3 Applications of Urological Cancer Drugs
1.3.1 Urological Cancer Drugs Consumption Market Share by Application in 2015
1.3.2 Prostate Cancer
1.3.3 Bladder Cancer
1.3.4 Kidney Cancer
1.3.5 Testicular Cancer
1.4 China Market Size (Value) of Urological Cancer Drugs (2012-2022)
1.5 China Urological Cancer Drugs Status and Outlook
1.6 Government Policies

2 China Urological Cancer Drugs Market Competition by Manufacturers
2.1 China Urological Cancer Drugs Capacity, Production and Share by Manufacturers (2015 and 2016)
2.2 China Urological Cancer Drugs Revenue and Share by Manufacturers (2015 and 2016)
2.3 China Urological Cancer Drugs Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Urological Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Urological Cancer Drugs Market Competitive Situation and Trends
2.5.1 Urological Cancer Drugs Market Concentration Rate
2.5.2 Urological Cancer Drugs Market Share of Top 3 and Top 5 Manufacturers

3 China Urological Cancer Drugs Manufacturers Profiles/Analysis
3.1 Novartis
3.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.1.2 Urological Cancer Drugs Product Type, Application and Specification
3.1.2.1 Xofigo (Radium Ra 223 Dichloride)
3.1.2.2 Jevtana (Cabazitaxel)
3.1.3 Novartis Urological Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.1.4 Main Business/Business Overview
3.2 Pfizer
3.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.2.2 Urological Cancer Drugs Product Type, Application and Specification
3.2.2.1 Xofigo (Radium Ra 223 Dichloride)
3.2.2.2 Jevtana (Cabazitaxel)
3.2.3 Pfizer 122 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.2.4 Main Business/Business Overview
3.3 Johnson & Johnson
3.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.3.2 Urological Cancer Drugs Product Type, Application and Specification
3.3.2.1 Xofigo (Radium Ra 223 Dichloride)
3.3.2.2 Jevtana (Cabazitaxel)
3.3.3 Johnson & Johnson 127 Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.3.4 Main Business/Business Overview
3.4 AstraZeneca
3.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.4.2 Urological Cancer Drugs Product Type, Application and Specification
3.4.2.1 Xofigo (Radium Ra 223 Dichloride)
3.4.2.2 Jevtana (Cabazitaxel)
3.4.3 AstraZeneca Jan Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.4.4 Main Business/Business Overview
3.5 Astellas
3.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.5.2 Urological Cancer Drugs Product Type, Application and Specification
3.5.2.1 Xofigo (Radium Ra 223 Dichloride)
3.5.2.2 Jevtana (Cabazitaxel)
3.5.3 Astellas Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.5.4 Main Business/Business Overview
3.6 Bristol-Myers Squibb
3.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.6.2 Urological Cancer Drugs Product Type, Application and Specification
3.6.2.1 Xofigo (Radium Ra 223 Dichloride)
3.6.2.2 Jevtana (Cabazitaxel)
3.6.3 Bristol-Myers Squibb Million USD Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.6.4 Main Business/Business Overview
3.7 Abbott Laboratories
3.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.7.2 Urological Cancer Drugs Product Type, Application and Specification
3.7.2.1 Xofigo (Radium Ra 223 Dichloride)
3.7.2.2 Jevtana (Cabazitaxel)
3.7.3 Abbott Laboratories Pharma & Healthcare Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.7.4 Main Business/Business Overview
3.8 Celgene Corporation
3.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.8.2 Urological Cancer Drugs Product Type, Application and Specification
3.8.2.1 Xofigo (Radium Ra 223 Dichloride)
3.8.2.2 Jevtana (Cabazitaxel)
3.8.3 Celgene Corporation Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.8.4 Main Business/Business Overview
3.9 Dendreon Corporation
3.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.9.2 Urological Cancer Drugs Product Type, Application and Specification
3.9.2.1 Xofigo (Radium Ra 223 Dichloride)
3.9.2.2 Jevtana (Cabazitaxel)
3.9.3 Dendreon Corporation Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.9.4 Main Business/Business Overview
3.10 Ferring Pharmaceuticals
3.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
3.10.2 Urological Cancer Drugs Product Type, Application and Specification
3.10.2.1 Xofigo (Radium Ra 223 Dichloride)
3.10.2.2 Jevtana (Cabazitaxel)
3.10.3 Ferring Pharmaceuticals Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
3.10.4 Main Business/Business Overview
3.11 GlaxoSmithKline
3.12 Indevus Pharmaceuticals Inc
3.13 Ipsen
3.14 Roche Healthcare
3.15 Sanofi S.A.
3.16 Tolmar Inc

4 China Urological Cancer Drugs Capacity, Production, Revenue, Consumption, Export and Import (2012-2017)
4.1 China Urological Cancer Drugs Capacity, Production and Growth (2012-2017)
4.2 China Urological Cancer Drugs Revenue and Growth (2012-2017)
4.3 China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

5 China Urological Cancer Drugs Production, Revenue (Value), Price Trend by Type
5.1 China Urological Cancer Drugs Production and Market Share by Type (2012-2017)
5.2 China Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
5.3 China Urological Cancer Drugs Price by Type (2012-2017)
5.4 China Urological Cancer Drugs Production Growth by Type (2012-2017)

6 China Urological Cancer Drugs Market Analysis by Application
6.1 China Urological Cancer Drugs Consumption and Market Share by Application (2012-2017)
6.2 China Urological Cancer Drugs Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Application
6.3.2 Emerging Markets/Countries

7 ChinaUrological Cancer Drugs Market Analysis by Regions (Provinces)
7.1 China Urological Cancer Drugs Production, Production Value and Price by Regions (Provinces)(2012-2017)
7.1.1 China Urological Cancer Drugs Production and Market Share by Regions (Provinces)(2012-2017)
7.1.2 China Urological Cancer Drugs Production Value and Market Share by Regions (Provinces)(2012-2017)
7.1.3 China Urological Cancer Drugs Sales Price by Regions (Provinces)(2012-2017)
7.2 China Urological Cancer Drugs Consumption by Regions (Provinces)(2012-2017)
7.3 China Urological Cancer Drugs Production, Consumption, Export and Import (2012-2017)

8 Urological Cancer Drugs Manufacturing Cost Analysis
8.1 Urological Cancer Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Urological Cancer Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Urological Cancer Drugs Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 China Urological Cancer Drugs Market Forecast (2017-2022)
12.1 China Urological Cancer Drugs Capacity, Production, Revenue Forecast (2017-2022)
12.2 China Urological Cancer Drugs Production, Import, Export and Consumption Forecast (2017-2022)
12.3 China Urological Cancer Drugs Production Forecast by Type (2017-2022)
12.4 China Urological Cancer Drugs Consumption Forecast by Application (2017-2022)
12.5 China Urological Cancer Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)
12.5.1 China Urological Cancer Drugs Production Forecast by Regions (Provinces)(2017-2022)
12.5.2 China Urological Cancer Drugs Consumption Forecast by Regions (Provinces)(2017-2022)
12.5.3 China Urological Cancer Drugs Production, Consumption, Import and Export Forecast by Regions (Provinces)(2017-2022)
12.6 Urological Cancer Drugs Price Forecast (2017-2022)

13 Research Findings and Conclusion

14 Appendix
Methodology
Analyst Introduction
Data Source


* indicates required information

* indicates required information


Share this Product


More from this collection